Hong et al. developed engineered enzymatic EVs with the native glycosylphosphatidylinositoll (GPI)-anchored form of hyaluronidase (Exo-PH20) to overcome the immunosuppressive tumor microenvironment [132] showing that the EV-mediated codelivery of PH20 hyaluronidase and a doxorubicin efficiently inhibits tumor growth. Here, SPAM1 is linked to neoplasm.